
## Kristopher K Frese

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9747746/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma. Clinical Cancer Research, 2022, 28, 1999-2019.	7.0	20
2	Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories. Open Biology, 2021, 11, 200247.	3.6	28
3	Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer. Nature Communications, 2021, 12, 6652.	12.8	14
4	The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report. Journal of Thoracic Oncology, 2020, 15, 1836-1843.	1.1	45
5	A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity. Nature Cancer, 2020, 1, 437-451.	13.2	103
6	<i>Ex vivo</i> culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics. British Journal of Pharmacology, 2019, 176, 436-450.	5.4	34
7	Will liquid biopsies improve outcomes for patients with small-cell lung cancer?. Lancet Oncology, The, 2018, 19, e470-e481.	10.7	63
8	The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 5153-5164.	7.0	126
9	Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin. Npj Genomic Medicine, 2018, 3, 15.	3.8	9
10	Next-Generation Sequencing Analysis and Algorithms for PDX and CDX Models. Molecular Cancer Research, 2017, 15, 1012-1016.	3.4	49
11	PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways. Scientific Reports, 2017, 7, 15441.	3.3	49
12	Targeting DNA damage in SCLC. Lung Cancer, 2017, 114, 12-22.	2.0	36
13	Circulating tumor cells and CDX models as a tool for preclinical drug development. Translational Lung Cancer Research, 2017, 6, 397-408.	2.8	68